Environment Trumps Health As FDA Ends Sales of Only OTC Asthma Inhaler in U.S.
The only over-the-counter asthma inhaler sold in the United States soon will be banned from store shelves because of environmental concerns, and replacement medications may cost more, the U.S. Food and Drug administration acknowledged.
The FDA announced on Wednesday that Primatene Mist (epinephrine) will be discontinued by the end of the year, as part of an international agreement to phase out chlorofluorocarbons and other ozone-depleting substances.
Primatene Mist, approved by the FDA for the temporary relief of occasional symptoms of mild asthma, uses chlorofluorocarbons as a propellant.
“If you have breathing problems but have not been diagnosed by a health care professional, it’s important to see one. Not all breathing problems are asthma, so you need to get an accurate diagnosis and the proper medicine,” Chowdhury said.
According to the FDA news release, “Replacement medicines for Primatene Mist may cost more.”